Actinium Pharmaceuticals Unveils Promising Preclinical Data for ATNM-400, Highlighting Durable Tumor Control in Resistant Prostate Cancer Models

Reuters

2025/10/13

Actinium Pharmaceuticals Unveils Promising Preclinical Data for ATNM-400, Highlighting Durable Tumor Control in Resistant Prostate Cancer Models

Actinium Pharmaceuticals Inc. has announced that preclinical data for its novel antibody radioconjugate, ATNM-400, will be presented at the 32nd Annual Prostate Cancer Foundation Scientific Retreat, scheduled for October 23-25, 2025, in Carlsbad, California. ATNM-400 is a first-in-class therapy armed with the alpha-emitter Actinium-225 and targets a non-PSMA antigen associated with prostate cancer progression. Preclinical studies have shown that ATNM-400 induces durable anti-tumor activity in metastatic castration-resistant prostate cancer models, including those resistant to standard-of-care therapies such as enzalutamide and 177Lu-PSMA-617. The company reports that ATNM-400 demonstrated efficacy independent of PSMA expression levels and outperformed current therapies in preclinical models. The results will be made available online following the conference presentation.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Actinium Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY95887) on October 13, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2575279406"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2575279406\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2575279406?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-13 20:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2575279406","market":"nz","top_or_hot":-1,"title":"Actinium Pharmaceuticals Unveils Promising Preclinical Data for ATNM-400, Highlighting Durable Tumor Control in Resistant Prostate Cancer Models","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Actinium Pharmaceuticals Unveils Promising Preclinical Data for ATNM-400, Highlighting Durable Tumor Control in Resistant Prostate Cancer Models\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Actinium Pharmaceuticals Inc. has announced that preclinical data for its novel antibody radioconjugate, ATNM-400, will be presented at the 32nd Annual Prostate Cancer Foundation Scientific Retreat, scheduled for October 23-25, 2025, in Carlsbad, California. ATNM-400 is a first-in-class therapy armed with the alpha-emitter Actinium-225 and targets a non-PSMA antigen associated with prostate cancer progression. Preclinical studies have shown that ATNM-400 induces durable anti-tumor activity in metastatic castration-resistant prostate cancer models, including those resistant to standard-of-care therapies such as enzalutamide and 177Lu-PSMA-617. The company reports that ATNM-400 demonstrated efficacy independent of PSMA expression levels and outperformed current therapies in preclinical models. The results will be made available online following the conference presentation.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Actinium Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY95887) on October 13, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Actinium Pharmaceuticals Unveils Promising Preclinical Data for ATNM-400, Highlighting Durable Tumor Control in Resistant Prostate Cancer Models</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nActinium Pharmaceuticals Unveils Promising Preclinical Data for ATNM-400, Highlighting Durable Tumor Control in Resistant Prostate Cancer Models\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-13 20:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Actinium Pharmaceuticals Unveils Promising Preclinical Data for ATNM-400, Highlighting Durable Tumor Control in Resistant Prostate Cancer Models\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Actinium Pharmaceuticals Inc. has announced that preclinical data for its novel antibody radioconjugate, ATNM-400, will be presented at the 32nd Annual Prostate Cancer Foundation Scientific Retreat, scheduled for October 23-25, 2025, in Carlsbad, California. ATNM-400 is a first-in-class therapy armed with the alpha-emitter Actinium-225 and targets a non-PSMA antigen associated with prostate cancer progression. Preclinical studies have shown that ATNM-400 induces durable anti-tumor activity in metastatic castration-resistant prostate cancer models, including those resistant to standard-of-care therapies such as enzalutamide and 177Lu-PSMA-617. The company reports that ATNM-400 demonstrated efficacy independent of PSMA expression levels and outperformed current therapies in preclinical models. The results will be made available online following the conference presentation.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Actinium Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY95887) on October 13, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251013:nNDL53R4yG:1","article_id":"2575279406","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2575279406","pubTimestamp":1760358709,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Actinium Pharmaceuticals Unveils Promising Preclinical Data for ATNM-400, Highlighting Durable Tumor Control in Resistant Prostate Cancer Models. Actinium Pharmaceuticals Inc. has announced that preclinical data for its novel antibody radioconjugate, ATNM-400, will be presented at the 32nd Annual Prostate Cancer Foundation Scientific Retreat, scheduled for October 23-25, 2025, in Carlsbad, California. ATNM-400 is a first-in-class therapy armed with the alpha-emitter Actinium-225 and targets a non-PSMA antigen associated with prostate cancer progression. Preclinical studies have shown that ATNM-400 induces durable anti-tumor activity in metastatic castration-resistant prostate cancer models, including those resistant to standard-of-care therapies such as enzalutamide and 177Lu-PSMA-617. The company reports that ATNM-400 demonstrated efficacy independent of PSMA expression levels and outperformed current therapies in preclinical models. The results will be made available online following","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","ATNM":"Actinium Pharmaceuticals, Inc."},"translate_title":"Actinium Pharmaceuticals公布了ATNM-400有希望的临床前数据，强调了耐药前列腺癌模型中的持久肿瘤控制","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ATNM":0.9},"content_text":"Actinium Pharmaceuticals Unveils Promising Preclinical Data for ATNM-400, Highlighting Durable Tumor Control in Resistant Prostate Cancer Models\n    \n\n        Actinium Pharmaceuticals Inc. has announced that preclinical data for its novel antibody radioconjugate, ATNM-400, will be presented at the 32nd Annual Prostate Cancer Foundation Scientific Retreat, scheduled for October 23-25, 2025, in Carlsbad, California. ATNM-400 is a first-in-class therapy armed with the alpha-emitter Actinium-225 and targets a non-PSMA antigen associated with prostate cancer progression. Preclinical studies have shown that ATNM-400 induces durable anti-tumor activity in metastatic castration-resistant prostate cancer models, including those resistant to standard-of-care therapies such as enzalutamide and 177Lu-PSMA-617. The company reports that ATNM-400 demonstrated efficacy independent of PSMA expression levels and outperformed current therapies in preclinical models. The results will be made available online following the conference presentation.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Actinium Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY95887) on October 13, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}